Organon & Co. Stock Prediction
AI-powered sentiment analysis and prediction trends for OGN, updated each market day.
OGN AI Sentiment
AI sees no strong directional signal for Organon & Co. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Organon & Co.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Sector
Exchange
Market Cap
$1,798,781,141
Cap Tier
Employees
10,000
Headquarters
JERSEY CITY, NJ
Listed Since
May 14, 2021
Website
OGN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
OGN Volatility
Organon & Co. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
